11 completed, 3 terminated, 3 unknown, 1 recruiting. 19 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 11, Terminated 3, Unknown 3, Recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Unknown 3, Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Urinary Incontinence, Urge: new trials by email Literature Review of Urinary Incontinence, Urge trials Research Report on Urinary Incontinence, Urge
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer Elidah Device - Urinary Urge Incontinence, Stress Urinary Incontinence | Phase 2 | Recruiting | National Cancer Institute (NCI) | 41 | 2024-02-15 | 2026-11-10 |
| Lidocaine Patches Prior to Percutaneous Nerve Evaluation Lidocaine patch, Placebo - Overactive Bladder, Urge Incontinence | Phase 2 | Completed | University of Louisville | 39 | 2023-05-01 | 2025-02-03 |
| URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence URO-902, Placebo - Overactive Bladder With Urge Urinary Incontinence | Phase 2 | Completed | Urovant Sciences GmbH | 80 | 2019-12-16 | 2023-04-20 |
| Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence Eluxadoline 100 mg, Placebo - Fecal Incontinence, Accidental Bowel Leakage | Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2019-04-01 | 2019-07-25 | |
| Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder Bryophyllum - Overactive Bladder, Urge Urinary Incontinence | Phase 2 / Phase 3 | Terminated | University of Zurich | 9 | 2014-05-01 | 2017-10-26 |
| Treatment of Urge Urinary Incontinence in Women After Failure of Cesa or Vasa TOT, solifenacin - Surgical Treatment of Urge Incontinence | Phase 1 / Phase 2 | Unknown | Klinikum der Universität Köln | 120 | 2013-01-01 | 2015-04-07 |
| Surgical vs. Medical Treatment of Urge Urinary Incontinence in Women solifenacin, cesa/vasa - Urge Urinary Incontinence | Phase 1 / Phase 2 | Unknown | Klinikum der Universität Köln | 120 | 2013-01-01 | 2015-04-07 |
| Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence UISH001, matching placebo - Urinary Incontinence | Phase 1 / Phase 2 | Completed | Beech Tree Labs, Inc. | 94 | 2011-04-01 | 2013-05-03 |
| Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency AOBO-001, Placebo - Overactive Bladder | Phase 2 | Completed | American Oriental Bioengineering, Inc. | 66 | 2010-12-01 | 2013-01-23 |
| Translating Unique Learning for Incontinence Prevention Instructional DVD, Bladder Health Class - Urinary Incontinence | Phase 2 | Completed | University of Michigan | 647 | 2010-09-01 | 2016-05-12 |
| Intravesical Instillation of Botulinum Toxin Type A to Patients With Urge Urinary Incontinence botulinum toxin type A - Urge Urinary Incontinence | Phase 1 / Phase 2 | Unknown | Glostrup University Hospital, Copenhagen | 20 | 2009-01-01 | 2009-08-04 |
| SSR240600C Treatment in Women With Overactive Bladder SSR240600C, tolterodine, placebo - Overactive Bladder | Phase 2 | Completed | Sanofi | 345 | 2007-11-01 | 2016-05-26 |
| A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence oxybutynin - Urinary Incontinence, Urge | Phase 2 | Completed | FemmePharma Global Healthcare, Inc. | 45 | 2007-07-01 | 2009-10-15 |
| Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity AV608 - Overactive Bladder Syndrome | Phase 2 | Terminated | Avera Pharmaceuticals | 62 | 2006-06-01 | 2008-02-25 |
| Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients GW679769 - Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder | Phase 2 | Terminated | GlaxoSmithKline | 1 | 2006-01-01 | 2015-04-17 |
| Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder. Botulinum Toxin A (Botox ) - Overactive Bladder | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 160 | 2005-11-01 | 2011-02-17 |
| Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder DR-3001a, DR-3001b, Placebo - Urinary Incontinence | Phase 2 | Completed | Duramed Research | 800 | 2004-10-01 | 2012-08-20 |
| Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder YM178, tolterodine, Placebo - Urinary Bladder, Overactive | Phase 2 | Completed | Astellas Pharma Europe B.V. | 260 | 2004-04-05 | 2024-10-31 |
| A Phase II Study of KUC-7483 in Patients With Overactive Bladder KUC-7483, Placebo - Overactive Bladder (OAB) | Phase 2 | Completed | Kissei Pharmaceutical Co., Ltd. | 400 | 2009-09-04 |
Urinary Bladder, Overactive (12) · Urinary Incontinence (6) · Urinary Incontinence, Stress (3) · Fecal Incontinence (2) · Diarrhea (1) · Encopresis (1) · Nocturnal Enuresis (1) · Prostatic Hyperplasia (1) · Prostatic Neoplasms (1) · Spinal Cord Injuries (1)
Female Urogenital Diseases (19) · Female Urogenital Diseases and Pregnancy Complications (19) · Lower Urinary Tract Symptoms (19) · Male Urogenital Diseases (19) · Pathological Conditions, Signs and Symptoms (19) · Signs and Symptoms (19) · Urination Disorders (19) · Urogenital Diseases (19) · Urologic Diseases (19) · Urological Manifestations (19) · Urinary Incontinence (13) · Urinary Bladder Diseases (12) · Behavior (2) · Behavioral Symptoms (2) · Digestive System Diseases (2)
Botulinum Toxins, Type A (2) · Solifenacin Succinate (2) · Tolterodine Tartrate (2) · Sugars (1) · casopitant (1) · eluxadoline (1) · mirabegron (1) · oxybutynin (1) · ritobegron ethyl (1)
Klinikum der Universität Köln (2) · American Oriental Bioengineering, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Astellas Pharma Europe B.V. (1) · Avera Pharmaceuticals (1) · Beech Tree Labs, Inc. (1) · Duramed Research (1) · FemmePharma Global Healthcare, Inc. (1) · GlaxoSmithKline (1) · Glostrup University Hospital, Copenhagen (1) · Kissei Pharmaceutical Co., Ltd. (1) · National Cancer Institute (NCI) (1) · Sanofi (1) · University of Louisville (1) · University of Michigan (1)
United States (10) · Germany (4) · Canada (2) · Czechia (2) · France (2) · Netherlands (2) · United Kingdom (2) · Belgium (1) · Denmark (1) · Japan (1) · Portugal (1) · Spain (1) · Sweden (1) · Switzerland (1)
Wolfram H Jager, PhD (2) · Carolyn Sampselle, PHD, RN (1) · Deborah E Citrin, M.D. (1) · Hanh Badger, PharmD (1) · Joao Siffert, MD (1) · Linda Cardozo, MD FRCOG (1) · Peter K. Mays, Ph.D. (1) · Tom Du, MD, PhD (1) · Yasuhiro Omori (1)
PMID 22036776, PMID 23218404, PMID 23424164, PMID 37160401, PMID 40013530
R01NR012011 (1)